CJC-1295 WITHOUT DAC Peptide Review
23December 23, 2022
CJC-1295 WITHOUT DAC Peptide Review
CJC-1295 WITHOUT DAC is a synthetic Growth Hormone Secretagogue (GHS). It is also called Growth Hormone Releasing Factor GRF1-29 because it contains the first 29 amino acids in Growth Releasing Factor. The drug affinity complex (DAC) version of CJC-1295 significantly extends the peptide’s half-life from around 30 minutes to 6-8 days, affecting dosing frequency and overall effectiveness, whereas the WITHOUT DAC version mimics more natural hormone pulsation but requires more frequent administration.
CJC-1295 WITHOUT DAC is available in lyophilized powder form and sold in 2mg vials.
At Loti Labs, we pride ourselves on stocking high-quality research chemicals. Buy CJC-1295 WITHOUT DAC for sale for research purposes only and not for human consumption.
WHAT IS CJC-1295 WITHOUT DAC
CJC-1295 WITHOUT DAC is a synthetic analog of the endogenous peptide signaling hormone Growth Hormone-Releasing Hormone (GHRH). Endogenously produced GHRH has 44 amino acids in its chain structure.
However, CJC-1295 WITHOUT DAC is a modified form of GHRH, designed to have the same activity and effect as the full-chain Growth Hormone Releasing Hormone (GHRH).
STRUCTURE OF CJC-1295 WITHOUT DRUG AFFINITY COMPLEX
Molecular Formula: C152H25N44O42
Molecular weight: 3367.9 g/mol
CAS number: 446262-90-4
MECHANISM OF ACTION AND GROWTH HORMONE RELEASE
CJC-1295 WITHOUT DAC is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, extending its half-life and duration of action. It has a half-life of 30 mins.
It causes a sustained, dose-dependent increase in GH and IGF-I levels in healthy animals by stimulating the anterior pituitary gland, which plays a crucial role in the release of growth hormone. This stimulation occurs in the pituitary gland, where CJC-1295 binds to GHRH receptors, triggering an increase in growth hormone secretion. The reliable release of growth hormone contributes to various health benefits, such as improved muscle mass and recovery.
CJC-1295 WITHOUT DAC EFFECTS
Current research on animal test subjects with CJC-1295 WITHOUT DAC has focused on finding potential benefits for the human body. The effects include:
Enhanced injury recovery rate.
Improvement of cardiovascular system strength
Increase in muscle mass and higher metabolism due to elevated plasma growth hormone levels
Improved ability to burn fat
Improvement of memory function and cognition
Increased bone density
Enhanced immune system
Improved sleep
A boosting of protein synthesis
CJC-1295 has gained further popularity due to its ability to facilitate the anterior pituitary gland’s natural pulsatile release of growth hormone, enhancing its associated benefits.
CJC-1295 WITHOUT DAC RESEARCH OBSERVATIONS
Laboratory investigations of CJC-1295 WITHOUT DAC have documented several research observations. These include:
Temporary energy depletion
Fluid accumulation in test subjects
Transient reduced sensitivity in peripheral regions
Dermal reaction at application site
Cranial discomfort
Altered gastrointestinal function
LABORATORY PROTOCOLS AND ADMINISTRATION QUANTITIES
In research settings, CJC-1295 administration methods include subcutaneous application or sublingual delivery systems. The appropriate quantities of CJC-1295 in studies vary according to the research objectives and experimental parameters. Typical investigation protocols utilize 1-2 mg per application, administered 1-3 times daily in laboratory settings. Research suggests that higher quantities do not necessarily correlate with improved outcomes, and administration protocols should be carefully calibrated to experimental requirements to prevent receptor adaptation. A scientist with specialized training in peptide research can establish optimal application quantities and timing for specific studies.
RESEARCH AND LABORATORY APPLICATIONS
Research suggests CJC-1295 may influence growth hormone levels in experimental settings, potentially leading to various areas of interest such as muscle tissue development, adipose reduction, and recovery rate modifications. Scientific studies have demonstrated that CJC-1295 appears to stimulate growth hormone release in controlled environments, with notable increases in GH levels observed particularly in rodent models. Additional scientific investigation is necessary to comprehensively understand the theoretical applications of this compound in various research contexts.
COMPARISON OF CJC-1295 WITH AND WITHOUT DAC
CJC-1295 with DAC has a longer half-life of 6-8 days, allowing for less frequent dosing. In contrast, CJC-1295 without DAC has a shorter half-life, typically around 30 minutes to an hour, requiring more frequent dosing. Both peptides share the same benefits, including faster recovery time, more muscle growth, and a reduction in fat. However, CJC-1295 with DAC may be more convenient for those who want fast results with less frequent dosing, while CJC-1295 without DAC may be more suitable for those who want a more natural effect and are willing to dose more frequently. Ultimately, the choice between CJC-1295 with or without DAC depends on personal preference and individual needs.
LOOKING FOR WHERE TO BUY CJC-1295 WITHOUT DAC ONLINE
When searching for research peptides online, it is paramount to buy from a trusted laboratory to ensure the integrity of your research.
Loti Labs offers affordable prices that come with quality control reports. We have in-depth customer support and a generous return policy when you buy CJC-1295 WITHOUT DAC for sale.
Visit our website or contact us today to buy CJC-1295 WITHOUT DAC online.
References:
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
Alba, M. et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology, Endocrinology, and Metabolism.
Jette, L. et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.
Teichman, Sam L., Neale, Ann, Lawrence, Betty, Gagnon, Catherine, Castaigne, Jean-Paul, & Frohman, Lawrence A. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. https://doi.org/10.1210/jc.2005-1536.
